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In December 2019, a novel coronavirus was first recognized in Wuhan, China1. On 30 January 2020, as infection rates and deaths across China soared and the first death outside China 
was recorded, the World Health Organization (WHO) described 
the then-unnamed disease as a Public Health Emergency of 
International Concern2. The disease was officially named coro-
navirus disease 2019 (COVID-19) by 11 February 20203, and was 
declared a pandemic on 11 March 20204. Since its first description 
in late 2019, the COVID-19 infection has spread across the globe, 
causing massive societal disruption and stretching our ability to 
deliver effective healthcare. This was caused by a lack of knowledge 
about the virus’s behaviour along with a lack of an effective vaccine 
and antiviral therapies.
Although PCR with reverse transcription (RT–PCR) is the test 
of choice for diagnosing COVID-19, imaging can complement its 
use to achieve greater diagnostic certainty or even be a surrogate 
in some countries where RT–PCR is not readily available. In some 
cases, chest radiograph (CXR) abnormalities are visible in patients 
who initially had a negative RT–PCR test5 and several studies have 
shown that chest computed tomography (CT) has a higher sensitiv-
ity for COVID-19 than RT–PCR, and could be considered as a pri-
mary tool for diagnosis6–9. In response to the pandemic, researchers 
have rushed to develop models using artificial intelligence (AI), in 
particular machine learning, to support clinicians.
Given recent developments in the application of machine learn-
ing models to medical imaging problems10,11, there is fantastic 
promise for applying machine learning methods to COVID-19 
radiological imaging for improving the accuracy of diagnosis, com-
pared with the gold-standard RT–PCR, while also providing valu-
able insight for prognostication of patient outcomes. These models 
have the potential to exploit the large amount of multimodal data 
collected from patients and could, if successful, transform detec-
tion, diagnosis and triage of patients with suspected COVID-19. 
Of greatest potential utility is a model that can not only distinguish 
patients with COVID-19 from patients without COVID-19 but also 
discern alternative types of pneumonia such as those of bacterial or 
other viral aetiologies. With no standardization, AI algorithms for 
COVID-19 have been developed with a very broad range of applica-
tions, data collection procedures and performance assessment met-
rics. Perhaps as a result, none are currently ready to be deployed 
clinically. Reasons for this include: (1) the bias in small datasets; 
(2) the variability of large internationally sourced datasets; (3) the 
poor integration of multistream data, particularly imaging data; (4) 
the difficulty of the task of prognostication; and (5) the necessity 
for clinicians and data analysts to work side-by-side to ensure the 
developed AI algorithms are clinically relevant and implementable 
into routine clinical care. Since the pandemic began in early 2020, 
researchers have answered the ‘call to arms’ and numerous machine 
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Machine learning methods offer great promise for fast and accurate detection and prognostication of coronavirus disease 2019 
(COVID-19) from standard-of-care chest radiographs (CXR) and chest computed tomography (CT) images. Many articles have 
been published in 2020 describing new machine learning-based models for both of these tasks, but it is unclear which are of 
potential clinical utility. In this systematic review, we consider all published papers and preprints, for the period from 1 January 
2020 to 3 October 2020, which describe new machine learning models for the diagnosis or prognosis of COVID-19 from CXR 
or CT images. All manuscripts uploaded to bioRxiv, medRxiv and arXiv along with all entries in EMBASE and MEDLINE in this 
timeframe are considered. Our search identified 2,212 studies, of which 415 were included after initial screening and, after 
quality screening, 62 studies were included in this systematic review. Our review finds that none of the models identified are of 
potential clinical use due to methodological flaws and/or underlying biases. This is a major weakness, given the urgency with 
which validated COVID-19 models are needed. To address this, we give many recommendations which, if followed, will solve 
these issues and lead to higher-quality model development and well-documented manuscripts.
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learning models for diagnosis and prognosis of COVID-19 using 
radiological imaging have been developed and hundreds of manu-
scripts have been written. In this Analysis, we reviewed the entire 
literature of machine learning methods as applied to chest CT and 
CXR for the diagnosis and prognosis of COVID-19. As this is a 
rapidly developing field, we reviewed both published and preprint 
studies to ensure maximal coverage of the literature.
While earlier reviews provided a broad analysis of predictive 
models for COVID-19 diagnosis and prognosis12–15, this Analysis 
highlights the unique challenges researchers face when developing 
classical machine learning and deep learning models using imag-
ing data. This Analysis builds on the approach of Wynants et al.12: 
we assess the risk of bias in the papers considered, going further by 
incorporating a quality screening stage to ensure only those papers 
with sufficiently documented methodologies are reviewed in most 
detail. We also focus our review on the systematic methodologi-
cal flaws in the current machine learning literature for COVID-19 
diagnosis and prognosis models using imaging data. We also give 
detailed recommendations in five domains: (1) considerations when 
collating COVID-19 imaging datasets that are to be made public; 
(2) methodological considerations for algorithm developers; (3) 
specific issues about reproducibility of the results in the literature; 
(4) considerations for authors to ensure sufficient documentation of 
methodologies in manuscripts; and (5) considerations for reviewers 
performing peer review of manuscripts.
This Analysis has been performed, and informed, by both clini-
cians and algorithm developers, with our recommendations aimed 
at ensuring the most clinically relevant questions are addressed 
appropriately, while maintaining standards of practice to help 
researchers develop useful models and report reliable results even 
in the midst of a pandemic.
Results
Study selection. Our initial search highlighted 2,212 papers that 
satisfied our search criteria; removing duplicates we retained 2,150 
papers, and of these, 415 papers had abstracts or titles deemed rele-
vant to the review question, introducing machine learning methods 
for COVID-19 diagnosis or prognosis using radiological imaging. 
Full-text screening retained 320 papers, of which, after quality 
review, 62 were included for discussion in this Analysis (Fig. 1). Of 
these, 37 were deep learning papers, 23 were traditional machine 
learning papers and 2 were hybrid papers (using both approaches).
Quality screening failures. Deep learning papers. There were 
254/320 papers that described deep learning-based models and 
215 of these were excluded from the detailed review (including one 
hybrid paper). We found that 110 papers (51%) fail at least three 
of our identified mandatory criteria from the CLAIM checklist 
(Supplementary Discussion 1), with 23% failing two and 26% failing 
just one. In the rejected papers, the three most common reasons for 
a paper failing the quality check was due to insufficient documenta-
tion of the following.
 (1) How the final model was selected in 61% (132)
 (2) The method of pre-processing of the images in 58% (125)
 (3) The details of the training approach (for example, the optimiz-
er, the loss function, the learning rate) in 49% (105)
Traditional machine learning papers. There were 69 papers that 
described traditional machine learning methods and 44 of these 
were excluded from the review, that is, the RQS was less than 6 or the 
datasets used were not specified in the paper. There were only two 
papers that had an RQS ≥6, but which failed to disclose the datasets 
used in the analysis. Of the remaining papers, the two factors that 
lead to the lowest RQS results were omission of the following.
 (1) Feature reduction techniques in 52% of papers (23)
 (2) Model validation in 61% of papers (27)
The two hybrid papers both failed the checklist for artificial 
intelligence in medical imaging (CLAIM) check but passed the 
radiomic quality score (RQS) criteria. Full details can be found in 
Supplementary Data 2.
Remaining papers for detailed analysis. Deep learning papers. 
There were six non-mandatory CLAIM criteria not satisfied in at 
least half of the 37 papers.
 (1) 29 did not complete any external validation
 (2) 30 did not perform any robustness or sensitivity analysis of 
their model
 (3) 26 did not report the demographics of their data partitions
 (4) 25 did not report the statistical tests used to assess significance 
of results or determine confidence intervals
 (5) 23 did not report confidence intervals for the performance





















Ineligible after CLAIM or
RQS review
258 papers
Papers included in our
review
62 papers
Does not introduce a new model or repurpose an existing model: 58
Does not use radiological features within a learning algorithm: 9
Duplicate: 4
Is not designed for diagnosis or prognosis of COVID-19: 18
Not in English: 5
Conflict of interest: 1
Fig. 1 | PRISMA flowchart for our systematic review. The flowchart highlights the inclusion and exclusion of papers at each stage.
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The full CLAIM results are in Supplementary Data 2.
Traditional machine learning papers. Of the 25 papers, including 
the two hybrid papers, none used longitudinal imaging, performed 
a prospective study for validation, or standardized image acquisi-
tion by using either a phantom study or a public protocol. Only 
six papers described performing external validation and only four 
papers reported the calibration statistics (the level of agreement 
between predicted risks and those observed) and associated statisti-
cal significance for the model predictions. The full RQS scores are 
in Supplementary Data 2.
Datasets considered. Public datasets were used extensively in the 
literature appearing in 32/62 papers (see Supplementary Discussion 
2 for list of public datasets, three papers use both public and pri-
vate data). Private data were used in 33/62 papers with 21 using 
data from mainland China, three using data from France and the 
remainder using data from Iran, the United States, Belgium, Brazil, 
Hong Kong and the Netherlands.
Diagnostic models for COVID-19. Diagnosis models using CXRs. 
Twenty-two papers considered diagnosis of COVID-19 from CXR 
images16–36. Most of these papers used off-the-shelf networks, includ-
ing ResNet-18 or ResNet-5016,17,20,26,29,32,37, DenseNet-12127,28,31,32,34, 
VGG-16 or VGG-1919,33,35, Inception21,38 and EfficientNet30,39, 
with three considering custom architectures18,25,36 and three using 
hand-engineered features22–24. Most papers classified images into 
the three classes, that is, COVID-19, non-COVID-19 pneumonia 
and normal16,19,21,23,25,26,28,30,32–37, while two considered an extra class 
by dividing non-COVID-19 pneumonia into viral and bacterial 
pneumonia17,29. ResNet and DenseNet architectures showed better 
performance than the others, with accuracies ranging from 0.88 to 
0.99. However, we caution against direct comparison as the papers 
use different training and testing settings (for example, different 
datasets and data partition sizes) and consider a different number 
of classes.
Diagnostic models using CT scans and deep learning. Eighteen papers 
applied deep learning techniques to CT imaging, all of which were 
framed as a classification task to distinguish COVID-19 from other 
lung pathologies such as (viral or bacterial) pneumonia, intersti-
tial lung disease35,40–47 and/or a non-COVID-19 class40,41,44,46,48–52. 
The full three-dimensional (3D) volumes were only considered in 
seven papers40,43,47,50,52–54 with the remainder considering isolated 2D 
slices or even 2D patches45. In most 2D models, authors employed 
transfer learning, with networks pre-trained on ImageNet55. Almost 
all models used lung segmentation as a pre-processing step. One 
paper48 used a generative adversarial network56 approach to address 
the paucity of COVID-19 CT imaging. Values reported for the area 
under the receiver operating characteristic curve (AUC) ranged 
from 0.70 to 1.00.
Diagnostic models using CT scans and traditional machine learning 
methods. Eight papers employed traditional machine learning meth-
ods for COVID-19 diagnosis using hand-engineered features40,57–62 
or convolutional neural network (CNN)-extracted features46. Four 
papers46,59,60,62 incorporated clinical features with those obtained 
from the CT images. All papers using hand-engineered features 
employed feature reduction, using between 4 and 39 features in 
their final models. For final classification, five papers used logistic 
regression40,58–61, one used a random forest57, one a multilayer per-
ceptron46 and one compared many different machine learning clas-
sifiers to determine the best62. Accuracies ranged from 0.76 to 0.98 
(refs. 40,46,57–59). As before, we caution against direct comparison. The 
traditional machine-learning model in the hybrid paper40 had a 0.05 
lower accuracy than their deep learning model.
Prognostic models for COVID-19 using CT and CXR images. 
Nineteen papers developed models for the prognosis of patients 
with COVID-1951,63–80, fifteen using CT and four using CXR. 
These models were developed for predicting severity of out-
comes including: death or need for ventilation72,78,79, a need for 
intensive care unit (ICU) admission63,73,77–79, progression to acute 
respiratory distress syndrome80, the length of hospital stay51,74, 
likelihood of conversion to severe disease64,65,75 and the extent 
of lung infection76. Most papers used models based on a multi-
variable Cox proportional hazards model51,72,78,79, logistic regres-
sion65,73–75,80, linear regression75,76, random forest74,77 or compare 
a huge variety of machine learning models such as tree-based 
methods, support vector machines, neural networks and nearest- 
neighbour clustering63,64.
Predictors from radiological data were extracted using either 
handcrafted radiomic features63,64,68–70,72,74,75,77–80 or deep learn-
ing51,66,70,71,73,76. Clinical data included basic observations, serology 
and comorbidities. Only eight models integrated both radiological 
and clinical data62,63,69,72,73,77–79.
Risks of bias. Following the prediction model risk of bias assess-
ment tool (PROBAST) guidance, the risk of bias was assessed for 
all 62 papers in four domains: participants, predictors, outcomes 
and analysis. The results are shown in Table 1. We found that 55/62 
papers had a high risk of bias in at least one domain with the others 
unclear in at least one domain.
Participants. Almost all papers had a high (45/62) or unclear (11/62) 
risk of bias for their participants, with only six assessed as having a 
low risk of bias. This was primarily due to the following issues: (1) for 
public datasets it is not possible to know whether patients are truly 
COVID-19 positive, or if they have underlying selection biases, as 
anybody can contribute images16,24,26,28–32,34,35,37,41,44,48,49,76; (2) the paper 
uses only a subset of original datasets, applying some exclusion cri-
teria, without enough details to be reproducible16,43,44,48,49,51,61,70,71,75,76; 
and/or (3) there are large differences in demographics between the 
COVID-19 cohort and the control groups, with, for example, paedi-
atric patients as controls17,24,28,29,31,32,35,37,45,46,59,81.
Predictors. For models where the features have been extracted using 
deep learning models, the predictors are unknown and abstract 
imaging features. Therefore, for these papers (38/62), we could not 
judge biases in the predictors. For 20 papers, the risk of bias was 
recorded as low due to the use of pre-defined hand-engineered fea-
tures. For the remaining 4 papers, a high risk of bias was recorded 
due to the predictors being assessed with knowledge of the associ-
ated outcome.
Outcomes. The risk of bias in the outcome variable was found to be 
low for the majority (25/62) of the papers, unclear for 26/62 and 
high for 11/62. To evaluate the bias in the outcome, we took differ-
ent approaches for papers using private datasets and public datasets 
(three papers use a mixture).
For the 35 papers that used public datasets, the outcome was 
assigned by the originators of the dataset and not by the papers’ 
authors. Papers that used a public dataset generally have an unclear 
risk of bias (30/35) as they used the outcome directly sourced from 
the dataset originator.
For the 33 papers that used private datasets, the COVID-19 diag-
nosis was due to either positive RT–PCR or antibody tests for 24/33 
and have a low risk of bias. The other papers have a high (7/33) or 
unclear (2/33) risk of bias due to inconsistent diagnosis of COVID-
1940,82, unclear definition of a control group63,65, ground truths being 
assigned using the images themselves26,54,60,71, using an unestablished 
reference to define outcome74 or by combining public and private 
datasets41,66,83.
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Table 1 | PROBAST results for each domain considered for each paper included in our systematic review
Reference Domain
Participants Predictors Outcomes Analysis
Ghoshal and Tucker17 High Unclear (DL) Unclear High
Li et al.34 Unclear Unclear (DL) Unclear High
Ezzat et al.28 High Unclear (DL) Unclear High
Tartaglione et al.16 High Unclear (DL) Unclear High
Luz et al.30 Unclear Unclear (DL) Unclear High
Bassi and Attux31 High Unclear (DL) Unclear High
Gueguim Kana et al.32 High Unclear (DL) Unclear High
Heidari et al.33 High Unclear (DL) Unclear Unclear
Farooq and Hafeez29 High Unclear (DL) Unclear High
Zhang et al.27 Low Unclear (DL) Low Unclear
Zhang et al.37 High Unclear (DL) Unclear High
Wang et al.26 High Unclear (DL) High High
Bararia et al.25 High Unclear (DL) Unclear High
Tsiknakis et al.21 High Unclear (DL) Unclear High
Malhotra et al.18 High High Unclear High
Sayyed et al.36 High Low Unclear High
Rahaman et al.19 High Unclear (DL) Unclear High
Amer et al.20 High Unclear (DL) Unclear High
Elaziz et al.22 High Low Unclear High
Tamal et al.24 High High Unclear High
Gil et al.23 High Low Unclear Unclear
Zokaeinikoo et al.35 High Unclear (DL) Unclear Unclear
Amyar et al.44 High Unclear (DL) Unclear High
Ardakani et al.45 High Unclear (DL) Low High
Bai et al.81 High Unclear (DL) Low Low
Jin et al.50 High Unclear (DL) Low Unclear
Wang et al.42 High Unclear (DL) Low Unclear
Ko et al.41 High Unclear (DL) High Low
Acar et al.48 High Unclear (DL) High Unclear
Pu et al.43 Unclear Unclear (DL) Low Unclear
Chen et al.49 High Unclear (DL) Unclear Unclear
Shah et al.52 High Unclear (DL) Unclear High
Han et al.47 High Unclear (DL) Unclear High
Wang et al.53 Unclear Unclear (DL) Low Low
Wang et al.54 High Unclear (DL) High Unclear
Goncharov et al.71 High Unclear (DL) High Low
Xie et al.61 High Low Low High
Xu et al.62 High Low Low Unclear
Qin et al.60 Low High High High
Georgescu et al.40 High Unclear (DL) High Unclear
Guiot et al.58 High Low Low Unclear
Shi et al.57 High Low Low Low
Mei et al.46 High Unclear (DL) Low High
Chen et al.59 High Low Low High
Wang et al.51 Unclear Unclear (DL) Low Low
Li et al.66 Low Unclear (DL) Unclear High
Li et al.67 LOW Unclear (DL) Low High
Continued
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Analysis. Only ten papers have a low risk of bias for their analy-
sis. The high risk of bias in most papers was principally due to a 
small sample size of patients with COVID-19 (leading to highly 
imbalanced datasets), use of only a single internal holdout set for 
validating their algorithm (rather than cross-validation or boot-
strapping) and a lack of appropriate evaluation of the performance 
metrics (for example, no discussion of calibration/discrimina-
tion)18–20,22,23,44,48,52,64,72,80. One paper with a high risk of bias32 claimed 
external validation on the dataset from ref. 84, not realizing that this 
already includes datasets from both ref. 85 and ref. 86 that were used 
to train the algorithm.
Data analysis. There are two approaches for validating the perfor-
mance of an algorithm, namely internal and external validation. For 
internal validation, the test data are from the same source as the 
development data and for external validation they are from differ-
ent sources. Including both internal and external validation allows 
more insight to generalizability of the algorithm. We found that 
48/62 papers consider internal validation only, with 13/62 using 
external validation22,32,41,42,51,54,63,66,67,69,73,78,79. Twelve used truly exter-
nal test datasets and one tested on the same data the algorithm was 
trained on32.
Model evaluation. In Table 2, we give the performance metrics quoted 
in each paper. Ten papers used cross-validation to evaluate model 
performance21,35,36,47,49,57,65,72,74,75,77, one used both cross-validation 
and an external test set41, one quoted correlation metrics76 and one 
had an unclear validation method17. The other papers all had an 
internal holdout or external test set with sensitivity and specificity 
derived from the test data using an unquoted operating point (with 
the exception of ref. 16, which quotes operating point 0.5). It would 
be expected that an operating point be chosen based on the algo-
rithm performance for the validation data used to tune and select 
the final algorithm. However, the receiver operating characteristic 
(ROC) curves and AUC values are given for the internal holdout or 
external test data independent of the validation data.
Partition analysis. In Fig. 2, we show the quantity of data (split 
by class) used in the training cohort of 32 diagnosis models. 
We excluded many studies18,20,22,23,25,28,29,32,35,43,45,58,71 because it was 
unclear how many images were used. If a paper only stated the 
number of patients (and not the number of images), we assumed 
that there was only one image per patient. We see that 20/32 papers 
have a reasonable balance between classes (with exceptions being 
refs. 17,24,26,30,31,33,36,37,40,51,61,62. However, the majority of datasets were 
quite small, with 19/32 papers using fewer than 2,000 datapoints for 
development (with exceptions being refs. 17,18,26,27,30,31,33,36,41,48,53,57,81). 
Only seven papers used both a dataset with more than 2,000 data-
points that was balanced for COVID-19 positive and the other 
classes27,41,48,53,54,57,81.
Figure 3 shows the number of images of each class used in the 
holdout/test cohorts. We found that 6/32 papers had an imbalanced 
testing dataset17,24,33,36,37,61. Only 6/32 papers tested on more than 
1,000 images17,27,36,41,54,81. Only 4/32 had both a large and balanced 
testing dataset27,41,54,81.
Public availability of the algorithms and models. Only 13/62 pap
ers21,23,27,30,34,36,46,51,66,67,74,76,81 published the code for reproducing their 
results (seven including their pre-trained parameters) and one 
stated that it is available on request74.
Discussion
Our systematic review highlights the extensive efforts of the inter-
national community to tackle the COVID-19 pandemic using 
machine learning. These early studies show promise for diagno-
sis and prognostication of pneumonia secondary to COVID-19. 
However, we have also found that current reports suffer from a high 
prevalence of deficiencies in methodology and reporting, with none 
of the reviewed literature reaching the threshold of robustness and 
reproducibility essential to support utilization in clinical practice. 
Many studies are hampered by issues with poor-quality data, poor 
application of machine learning methodology, poor reproducibil-
ity and biases in study design. The current paper complements 
the work of Wynants et al. who have published a living systematic 
review12 on publications and preprints of studies describing multi-
variable models for screening of COVID-19 infections in the gen-
eral population, differential diagnosis of COVID-19 infection in 
patients that are symptomatic and prognostication in patients with 
Reference Domain
Participants Predictors Outcomes Analysis
Schalekamp et al.68 Unclear Low Low Low
Cohen et al.76 High Unclear (DL) Unclear Unclear
Yue et al.74 High Low High High
Zhu et al.75 High Low Low Low
Lassau et al.73 High Unclear (DL) High Unclear
Chassagnon et al.63 Unclear Low Low Unclear
Chao et al.77 Low Low Low High
Wu et al.78 Unclear Low Low High
Zheng et al.79 Unclear Low Low High
Chen et al.80 High Low Low High
Ramtohul et al.72 Unclear Low Low High
Ghosh et al.64 High High High Low
Wei et al.65 Low Low High High
Wang et al.69 Unclear Low Low Low
Yip et al.70 High Low Unclear Unclear
DL, deep learning.
Table 1 | PROBAST results for each domain considered for each paper included in our systematic review
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Unclear in the 
paper














DL Unclear in the 
paper











Diagnosis CT DL 944 patients, 
399 COVID-19
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splits do not 
total correctly
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Jin et al.50 Diagnosis CT DL 1,136 images, 
723 COVID-19








Wang et al.42 Diagnosis CT DL 320 images, 
160 COVID-19
Internal validation: 
455 images, 95 
COVID-19
External validation: 

















799 (CV) images, 
239 COVID-19
External validation: 
















Acar et al.48 Diagnosis CT DL 2,552 
images, 1,085 
COVID-19








recall, 1.00; F1 
score, 1.00
No
Pu et al.43 Diagnosis CT DL Unclear in the 
paper

























Shah et al.52 Diagnosis CT DL 664 images, 
314 COVID-19





Han et al.47 Diagnosis CT DL 368 (CV) 
images, 184 
COVID-19







Wang et al.53 Diagnosis CT DL 3,997 
images, 1,095 
COVID-19
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Xie et al.61 Diagnosis CT Hand-engineered 
radiomic features
225 images, 27 
COVID-19





















Qin et al.60 Diagnosis CT Hand-engineered 
radiomic features
118 patients, 62 
COVID-19

























Guiot et al.58 Diagnosis CT Hand-engineered 
radiomic features
Unclear in the 
paper
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98 patients, 51 
COVID-19










Wang et al.51 Diagnosis 
and prognosis 
for length of 
hospital stay
CT Diagnosis model: 
DL
Prognosis model: 






226 images, 102 
COVID-19
Validation 2: 
161 images, 92 
COVID-19
Validation 3: 53 
images, all with 
length of hospital 
stay
Validation 4: 117 
images, all with 
length of hospital 
stay















Li et al.66 Prognosis for 
severity

















Li et al.67 Prognosis for 
severity
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26 patients, 16 
long term
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NPV, 1.00; PPV, 
0.80
Yesd
Zhu et al.75 The prognosis 
for whether 
patients will 










Unclear in the 
paper







































150 images, all 
COVID-19, 48 with 
severe outcome
External validation: 
135 patients, all 
with COVID-19, 






























19, 108 severe 
short-term 
outcomes, 
unclear for long 
term
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used for testing 
of the algorithm, 
along with the 
number of positive 
outcomes.
k-fold CV, external 
validation in 




























59 (CV) images, 
31 admitted to ICU
Fivefold internal 
cross-validation
Unclear in the 
paper
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141 images, 26 
severe outcomes











Zheng et al.79 Prognosing 
for admission 










72 images, 10 
severe outcomes
External validation C index, 0.89 No








247 images, 36 
severe cases

















24 images, unclear 


























C index, 0.83 
[0.73, 0.93]
No





Unclear in the 
paper














161 patients, 15 
non-survivors
135 patients, 
unclear number of 
non-survivors




















aNumber of samples after augmentation, the original number of COVID-19 images is unclear. bThe authors state that the algorithm will be made publicly available. cThe paper states that code ‘is available on 
a public GitHub repository’ but no link is provided and the authors could not locate it. dThe authors state that ‘imaging or algorithm data used in this study are available upon request’. w, weighted average; 
CV, cross-validation; CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value; KM, Kaplan–Meier; GGOs, ground-glass opacities.
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this systematic review employed specialized quality metrics for 
the assessment of radiomics and deep learning-based diagnostic 
models in radiology. This is also in contrast to previous studies that 
have assessed AI algorithms in COVID-1913,14. Limitations of the 
current literature most frequently reflect either a limitation of the 
dataset used in the model or methodological mistakes repeated in 
many studies that probably lead to overly optimistic performance 
evaluations.
Datasets. Many papers gave little attention to establishing the origi-
nal source of the images (Supplementary Discussion 2). When con-
sidering papers that use public data, readers should be aware of the 
following.
Duplication and quality issues. There is no restriction for a contribu-
tor to upload COVID-19 images to many of the public reposito-
ries85,87–90. There is high likelihood of duplication of images across 
these sources and no assurance that the cases included in these 
datasets are confirmed COVID-19 cases (authors take a great leap 
to assume this is true) so great care must be taken when combining 
datasets from different public repositories. Also, most of the images 
have been pre-processed and compressed into non-DICOM formats 
leading to a loss in quality and a lack of consistency/comparability.
•	 Source issues. Many papers (16/62) used the pneumonia dataset 
of Kermany et al.86 as a control group. They commonly failed to 
mention that this consists of paediatric patients aged between 
one and five. Developing a model using adult patients with 
COVID-19 and very young patients with pneumonia is likely to 
overperform as it is merely detecting children versus adults. This 
dataset is also erroneously referred to as the Mooney dataset in 
many papers (being the Kermany dataset deployed on Kaggle91). 
It is also important to consider the sources of each image class, 
for example, if images for different diagnoses are from different 
sources. It is demonstrated by Maguolo et al.92 that by excluding 
the lung region entirely, the authors could identify the source 
of the images in the Cohen et al.85 and Kermany et al.86 data-
sets with an AUC between 0.9210 and 0.9997, and ‘diagnose’ 
COVID-19 with an AUC = 0.68.
•	 Frankenstein datasets. The issues of duplication and source 
become compounded when public ‘Frankenstein’ datasets are 
used, that is, datasets assembled from other datasets and redis-
tributed under a new name. For instance, one dataset91 com-
bined several other datasets85,88,93 without realizing that one 
of the component datasets93 already contains another compo-
nent88. This repackaging of datasets, although pragmatic, inevi-
tably leads to problems with algorithms being trained and tested 
on identical or overlapping datasets while believing them to be 
from distinct sources.
•	 Implicit biases in the source data. Images uploaded to a public 
repository and those extracted from publications93 are likely to 
have implicit biases due to the contribution source. For exam-
ple, it is likely that more interesting, unusual or severe cases of 
COVID-19 appear in publications.
Methodology. All proposed models suffer from a high or unclear 
risk of bias in at least one domain. There are several methodologi-
cal issues driven by the urgency in responding to the COVID-19 
crisis and subtler sources of bias due to poor application of machine 
learning.
The urgency of the pandemic led to many studies using datasets 
that contain obvious biases or are not representative of the target 
population, for example, paediatric patients. Before evaluating a 
model, it is crucial that authors report the demographic statistics 
for their datasets, including age and sex distributions. Diagnostic 
studies commonly compare their models’ performance to that of 








































































































































































































































Fig. 2 | The number of images used in each paper for model training split by image class. It is noted that we exclude Bai et al.81 from the figure as they 
used much more training data (118,401 images) than other papers. For Xu et al.62, two COVID-19 classes are shown in the graph as one combined class.
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by RT–PCR, there is no way to measure whether a model outper-
forms RT–PCR from accuracy, sensitivity or specificity metrics 
alone. Ideally, models should aim to match clinicians using all avail-
able clinical and radiomic data, or to aid them in decision-making.
Many papers utilized transfer learning in developing their model, 
which assumes an inherent benefit to performance. However, it is 
unclear whether transfer learning offers a large performance benefit 
due to the over-parameterization of the models41,58. Many publica-
tions used the same resolutions such as 224-by-224 or 256-by-256 
for training, which are often used for ImageNet classification, indi-
cating that the pre-trained model dictated the image rescaling used 
rather than clinical judgement.
Recommendations. Based on the systematic issues we encountered 
in the literature, we offer recommendations in five distinct areas: (1) 
the data used for model development and common pitfalls; (2) the 
evaluation of trained models; (3) reproducibility; (4) documenta-
tion in manuscripts; and (5) the peer-review process. Our recom-
mendations in areas (3) and (4) are largely informed by the 258 
papers that did not pass our initial quality check, while areas (1), 
(2) and (5) follow from our analysis of the 62 papers receiving our 
full review.
Recommendations for data. First, we advise caution over the use of 
public repositories, which can lead to high risks of bias due to source 
issues and Frankenstein datasets as discussed above. Furthermore, 
authors should aim to match demographics across cohorts, an often 
neglected but important potential source of bias; this can be impos-
sible with public datasets that do not include demographic informa-
tion, and including paediatric images86 in the COVID-19 context 
introduces a strong bias.
Using a public dataset alone without additional new data can lead 
to community-wide overfitting on this dataset. Even if each indi-
vidual study observes sufficient precautions to avoid overfitting, the 
fact that the community is focused on outperforming benchmarks 
on a single public dataset encourages overfitting. Many public data-
sets containing images taken from preprints receive these images 
in low-resolution or compressed formats (for example, JPEG and 
PNG), rather than their original DICOM format. This loss of reso-
lution is a serious concern for traditional machine learning models 
if the loss of resolution is not uniform across classes, and the lack of 
DICOM metadata does not allow exploration of model dependence 
on image acquisition parameters (for example, scanner manufac-
turer, slice thickness and so on).
Regarding CXRs, researchers should be aware that algorithms 
might associate more severe disease not with CXR imaging features, 
but the view that has been used to acquire that CXR. For example, 
for patients that are sick and immobile, an anteroposterior CXR 
view is used for practicality rather than the standard posteroanterior 
CXR projection. Also, overrepresentation of severe disease is bad 
not only from the machine learning perspective but also in terms 
of clinical utility, as the most useful algorithms are those that can 
diagnose disease at an early stage94. The timing between imaging 
and RT–PCR tests was also largely undocumented, which has impli-
cations for the validity of the ground truth used. It is also important 
to recognize that a negative RT–PCR test does not necessarily mean 
that a patient does not have COVID-19. We encourage authors to 
evaluate their algorithms on datasets from the pre-COVID-19 era, 
such as performed by ref. 95, to validate any claims that the algo-
rithm is isolating COVID-19-specific imaging features. It is com-
mon for non-COVID-19 diagnoses (for example, non-COVID-19 
































































































































































































































Fig. 3 | The number of images used for model testing split by image class. It is noted that we exclude Bai et al.81 and Zhang et al.27 from the figure as they 
used far more testing data (14,182 and 5,869 images respectively) than other papers. There were a large number of images (1,237) in the testing dataset in 
Wang et al.54 that were unidentified in the paper (we include these in the unspecified COVID-19 negative).
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many cases, these images are the only predictors of the developed 
model, and using predictors to inform outcomes leads to optimistic 
performance.
Recommendations for evaluation. We emphasize the importance of 
using a well-curated external validation dataset of appropriate size to 
assess generalizability to other cohorts. Any useful model for diagno-
sis or prognostication must be robust enough to give reliable results 
for any sample from the target population rather than just on the 
sampled population. Calibration statistics should be calculated for 
the developed models to inform predictive error and decision curve 
analysis96 performed for assessing clinical utility. It is important for 
authors to state how they ensured that images from the same patient 
were not included in the different dataset partitions, such as describ-
ing patient-level splits. This is an issue for approaches that consider 
2D and 3D images as a single sample and also for those that process 
3D volumes as independent 2D samples. It is also important when 
using datasets containing multiple images from each patient. When 
reporting results, it is important to include confidence intervals 
to reflect the uncertainty in the estimate, especially when training 
models on the small sample sizes commonly seen with COVID-
19 data. Moreover, we stress the importance of not only reporting 
results but also demonstrating model interpretability with methods 
such as saliency maps, which is a necessary consideration for adop-
tion into clinical practice. We remind authors that it is inappropri-
ate to compare model performance to RT–PCR or any other ground 
truths. Instead, authors should aim for models to either improve 
the performance and efficiency of clinicians, or, even better, to aid 
clinicians by providing interpretable predictions. Examples of inter-
pretability techniques include: (1) informing the clinician of which 
features in the data most influenced the prediction of the model, 
(2) linking the prognostic features to the underlying biology and (3) 
overlaying an activation/saliency map on the image to indicate the 
region of the image that influenced the model’s prediction, and (4) 
identifying patients that had a similar clinical pathway.
Most papers derive their performance metrics from the test 
data alone with an unstated operating point to calculate sensitiv-
ity and specificity. Clinical judgement should be used to identify 
the desired sensitivity or specificity of the model and the operating 
point should be derived from the development data. The differences 
in the sensitivity and specificity of the model should be recorded 
separately for the validation and test data. Using an operating point 
of 0.5 and only reporting the test sensitivity and specificity fails to 
convey the reliability of the threshold. This is a key aspect of gen-
eralizability. Omitting it, in the process of device regulation, would 
see a US Food and Drug Administration 510K submission rejected.
Recommendations for replicability. A possible ambiguity arises due 
to updating of publicly available datasets or code. Therefore, we rec-
ommend that a cached version of the public dataset be saved, or 
the date/version quoted, and specific versions of data or code be 
appropriately referenced. (Git commit ids or tags can be helpful for 
this purpose to reference a specific version on GitHub, for example.) 
We acknowledge that although perfect replication is potentially not 
possible, details such as the seeds used for randomness and the 
actual partitions of the dataset for training, validation and testing 
would form very useful supplementary materials.
Recommendations for authors. For authors, we recommend assess-
ing their paper against appropriate established frameworks, such 
as RQS, CLAIM, transparent reporting of a multivariable pre-
diction model for individual prognosis or diagnosis (TRIPOD), 
PROBAST and Quality Assessment of Diagnostic Accuracy Studies 
(QUADAS)97–101. By far the most common point leading to exclusion 
was failure to state the data pre-processing techniques in sufficient 
detail. As a minimum, we expected papers to state any image resizing, 
cropping and normalization used before model input, and with this 
small addition many more papers would have passed through the 
quality review stage. Other commonly missed points include details 
of the training (such as number of epochs and stopping criteria), 
robustness or sensitivity analysis, and the demographic or clinical 
characteristics of patients in each partition.
Recommendations for reviewers. For reviewers, we also recommend 
the use of the checklists97–101 to better identify common weaknesses 
in reporting the methodology. The most common issues in the 
papers we reviewed was the use of biased datasets and/or method-
ologies. For non-public datasets, it may be difficult for reviewers 
to assess possible biases if an insufficiently detailed description is 
given by the authors. We strongly encourage reviewers to ask for 
clarification from the authors if there is any doubt about bias in the 
model being considered. Finally, we suggest using reviewers from a 
combination of both medical and machine learning backgrounds, 
as they can judge the clinical and technical aspects in different ways.
Challenges and opportunities. Models developed for diagnosis 
and prognostication from radiological imaging data are limited by 
the quality of their training data. While many public datasets exist 
for researchers to train deep learning models for these purposes, we 
have determined that these datasets are not large enough, or of suit-
able quality, to train reliable models, and all studies using publicly 
available datasets exhibit a high or unclear risk of bias. However, the 
size and quality of these datasets can be continuously improved if 
researchers worldwide submit their data for public review. Because 
of the uncertain quality of many COVID-19 datasets, it is likely 
more beneficial to the research community to establish a database 
that has a systematic review of submitted data than it is to immedi-
ately release data of questionable quality as a public database.
The intricate link of any AI algorithm for detection, diagnosis 
or prognosis of COVID-19 infections to a clear clinical need is 
essential for successful translation. As such, complementary com-
putational and clinical expertise, in conjunction with high-quality 
healthcare data, are required for the development of AI algorithms. 
Meaningful evaluation of an algorithm’s performance is most likely 
to occur in a prospective clinical setting. Like the need for collab-
orative development of AI algorithms, the complementary perspec-
tives of experts in machine learning and academic medicine were 
critical in conducting this systematic review.
Limitations. Due to the fast development of diagnostic and prog-
nostic AI algorithms for COVID-19, at the time of finalizing our 
analyses, several new preprints have been released; these are not 
included in this study.
Our study has limitations in terms of methodologic quality and 
exclusion. Several high-quality papers published in high-impact 
journals—including Radiology, Cell and IEEE Transactions on 
Medical Imaging—were excluded due to the lack of documentation 
on the proposed algorithmic approaches. As the AI algorithms are 
the core for the diagnosis and prognosis of COVID-19, we only 
included works that are reproducible. Furthermore, we acknowl-
edge that the CLAIM requirements are harder to fulfil than the RQS 
ones, and the paper quality check is therefore not be fully compa-
rable between the two. We underline that several excluded papers 
were preprint versions and may possibly pass the systematic evalu-
ation in a future revision.
In our PROBAST assessment, for the ‘Were there a reason-
able number of participants?’ question of the analysis domain, we 
required a model to be trained on at least 20 events per variable 
for the size of the dataset to score a low risk of bias100. However, 
events per variable may not be a useful metric to determine 
whether a deep learning model will overfit. Despite their gross 
over-parameterization, deep learning models generalize well in 
NATURE MACHINE INTELLIGENCE | VOL 3 | MARCH 2021 | 199–217 | www.nature.com/natmachintell 213
AnAlysis NATuRE MAChINE INTELLIgENCE
a variety of tasks, and it is difficult to determine a priori whether 
a model will overfit given the number of training examples102. A 
model that was trained using fewer than 500 COVID-19 positive 
images was deemed to have a high risk of bias in answer to this 
and more than 2,000 COVID-19 positive images qualified as low 
risk. However, in determining the overall risk of bias for the analysis 
domain, we factor in nine PROBAST questions, so it is possible for 
a paper using fewer than 500 images to achieve at best an unclear 
overall risk of bias for its analysis. Similarly, it is possible for papers 
that have over 2,000 images to have an overall high risk of bias for 
their analysis if it does not account for other sources of bias.
Conclusions
This systematic review specifically considers the current machine 
learning literature using CT and CXR imaging for COVID-19 diag-
nosis and prognosis, which emphasizes the quality of the method-
ologies applied and the reproducibility of the methods. We found 
that no papers in the literature currently have all of: (1) a sufficiently 
documented manuscript describing a reproducible method; (2) a 
method that follows best practice for developing a machine learn-
ing model; and (3) sufficient external validation to justify the wider 
applicability of the method. We give detailed specific recommenda-
tions for data curators, machine learning researchers, manuscript 
authors and reviewers to ensure the best-quality methods are devel-
oped that are reproducible and free from biases in either the under-
lying data or the model development.
Despite the huge efforts of researchers to develop machine learn-
ing models for COVID-19 diagnosis and prognosis, we found meth-
odological flaws and many biases throughout the literature, leading 
to highly optimistic reported performance. In their current reported 
form, none of the machine learning models included in this review 
are likely candidates for clinical translation for the diagnosis/prog-
nosis of COVID-19. Higher-quality datasets, manuscripts with suf-
ficient documentation to be reproducible and external validation 
are required to increase the likelihood of models being taken for-
ward and integrated into future clinical trials to establish indepen-
dent technical and clinical validation as well as cost-effectiveness.
Methods
The methods for performing this systematic review are registered with PROSPERO 
(CRD42020188887) and were agreed by all authors before the start of the review 
process, to avoid bias.
Search strategy and selection criteria. We followed the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) checklist103 and include 
this in Supplementary Table 1. We performed our search to identify published 
and unpublished works using the arXiv and the ‘Living Evidence on COVID-19’ 
database104, a collation of all COVID-19 related papers from EMBASE via OVID, 
MEDLINE via PubMed, bioRxiv and medRxiv. The databases were searched from 
1 January 2020 to 3 October 2020. The full search strategy is detailed in ‘Search 
strategy’. The initial cut-off is chosen to specifically include all early COVID-19 
research, given that the WHO was only informed of the ‘pneumonia of unknown 
cause’ on 31 December 2019105. An initial search was performed on 28 May 2020, 
with updated searches performed on 24 June 2020, 14 August 2020, 15 August 
2020 and 3 October 2020 to identify any relevant new papers published in the 
intervening period. As many of the papers identified are preprints, some of them 
were updated or published between these dates; in such cases, we used the preprint 
as it was at the later search date or the published version. Some papers were 
identified as duplicates ourselves or by Covidence106; in these instances, we ensured 
that the latest version of the paper was reviewed. We used a three-stage process to 
determine which papers would be included in this review. During the course of 
the review, one author (A.I.A.-R.) submitted a paper107 that was in scope for this 
review; however, we excluded it due to the potential for conflict of interest.
Title and abstract screening. In the first stage, a team of ten reviewers assessed 
papers for eligibility, screening the titles and abstracts to ensure relevance. Each 
paper was assessed by two reviewers independently and conflicts were resolved by 
consensus of the ten reviewers (Supplementary Data 1).
Full-text screening. In the second stage, the full text of each paper was screened by 
two reviewers independently to ensure that the paper was eligible for inclusion 
with conflicts resolved by consensus of the ten reviewers.
Quality review. In the third stage, we considered the quality of the documentation 
of methodologies in the papers. Note that exclusion at this stage is not a judgement 
on the quality or impact of a paper or algorithm, merely that the methodology is 
not documented with enough detail to allow the results to be reliably reproduced.
At this point, we separated machine learning methods into deep learning 
methods and non-deep learning methods (we refer to these as traditional machine 
learning methods). The traditional machine learning papers were scored using 
the RQS of Lambin et al.97, while the deep learning papers were assessed against 
the CLAIM of Mongan et al.98. The ten reviewers were assigned to five teams of 
two: four of the ten reviewers have a clinical background and were paired with 
non-clinicians in four of the five teams to ensure a breadth of experience when 
reviewing these papers. Within each team, the two reviewers independently 
assessed each paper against the appropriate quality measure. Where papers 
contained both deep learning and traditional machine learning methodologies, 
these were assessed using both CLAIM and RQS. Conflicts were resolved by a third 
reviewer.
To restrict consideration to only those papers with the highest-quality 
documentation of methodology, we excluded papers that did not fulfil particular 
CLAIM or RQS requirements. For the deep learning papers evaluated using the 
CLAIM checklist, we selected eight checkpoint items deemed mandatory to allow 
reproduction of the paper’s method and results. For the traditional machine 
learning papers, evaluated using the RQS, we used a threshold of 6 points out of 
36 for inclusion in the review along with some basic restrictions, such as detail of 
the data source and how subsets were selected. The rationale for these CLAIM and 
RQS restrictions is given in Supplementary Discussion 1. If a paper was assessed 
using both CLAIM and RQS then it only needed to pass one of the quality checks 
to be included.
In a number of cases, various details of pre-processing, model configuration or 
training setup were not discussed in the paper, even though they could be inferred 
from a referenced online code repository (typically GitHub). In these cases, we 
have assessed the papers purely on the content in the paper, as it is important to be 
able to reproduce the method and results independently of the authors’ code.
Risk of bias in individual studies. We use the PROBAST of Wolff et al.100 to 
assess bias in the datasets, predictors and model analysis in each paper. The papers 
that passed the quality assessment stage were split among three teams of two 
reviewers to complete the PROBAST review. Within each team, the two reviewers 
independently scored the risk of bias for each paper and then resolved by conflicts 
any remaining conflicts were resolved by a third reviewer.
Data analysis. The papers were allocated among five teams of two reviewers. 
These reviewers independently extracted the following information: (1) 
whether the paper described a diagnosis or prognosis model; (2) the data used 
to construct the model; (3) whether there were predictive features used for 
the model construction; (4) the sample sizes used for the development and 
holdout cohorts (along with the number of COVID-19 positive cases); (5) the 
type of validation performed; (6) the best performance quoted in the paper for 
the validation cohort (whether internal, external or both); and (7) whether the 
code for training the model and the trained model were publicly available. Any 
conflicts were initially resolved by team discussions and remaining conflicts were 
resolved by a third reviewer.
Role of the funding source. The funders of the study had no role in the study 
design, data collection, data analysis, data interpretation or writing of the 
manuscript. All authors had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Search strategy. Initial extraction. For the arXiv papers, we initially extracted 
papers for the relevant date ranges that included ‘ncov’ (as a complete word), 
‘coronavirus’, ‘covid’, ‘sars-cov-2’ or ‘sars-cov2’ in their title or abstract. For the 
‘Living Evidence on COVID-19’ database104, we downloaded all papers in the 
appropriate date range.
Refined search. We then filtered the identified papers using the following criteria: 
title or abstract contain one of: ‘ai’, ’deep’, ’learning’, ‘machine’, ‘neural’, ‘intelligence’, 
‘prognos’, ‘diagnos’, ‘classification’, ‘ segmentation’ and also contain one of ‘ct’, ‘cxr’, 
‘x-ray’, ‘xray’, ‘imaging’, ‘image’, ‘radiograph’. Only ‘ai’, ‘ct’ and ‘cxr’ are required to 
be complete words. This differs slightly from the original PROSPERO description; 
the search was widened to identify some additional papers. The full history of the 
searching and filtering source code can be explored at https://gitlab.developers.
cam.ac.uk/maths/cia/covid-19-systematic-review
Data availability
All data generated or analysed during this study are included in this published 
article (and its supplementary information files).
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